Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00022646 · ClinicalTrials.gov registry record · Phase 2

Pemetrexed Disodium Plus Gemcitabine in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

A Phase 2 study of Lung Cancer, sponsored by Alliance for Clinical Trials in Oncology.

Completed
Registry status
Phase 2
Development phase
157
Enrollment target
20
Study locations

NCT00022646 is a Phase 2 study of Lung Cancer that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 157 participants, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (83% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00022646, a Phase 2 study of Lung Cancer, has completed, sponsored by Alliance for Clinical Trials in Oncology.

COMPLETED
Registry status
Phase 2
Development phase
157 participants
Enrollment target
20
Study locations

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug and giving the drugs in different ways may kill more tumor cells. PURPOSE: Randomized phase II trial to compare the effectiveness of three different regimens of pemetrexed disodium plus gemcitabine in treating patients who have locally advanced or metastatic non-small cell lung cancer.

Conditions Studied

Lung Cancer

Interventions

  • DRUG gemcitabine hydrochloride
  • DRUG pemetrexed disodium

Study Locations (20)

Minnesota

  • CCOP - Duluth - Duluth
  • Mayo Clinic Cancer Center - Rochester
  • CentraCare Health Plaza - Saint Cloud
  • CCOP - Metro-Minnesota - Saint Louis Park

Iowa

  • CCOP - Cedar Rapids Oncology Project - Cedar Rapids
  • CCOP - Iowa Oncology Research Association - Des Moines
  • Siouxland Hematology-Oncology - Sioux City

North Dakota

  • Medcenter One Health System - Bismarck
  • CCOP - Merit Care Hospital - Fargo
  • Altru Health Systems - Grand Forks

Illinois

  • CCOP - Illinois Oncology Research Association - Peoria
  • CCOP - Carle Cancer Center - Urbana

Pennsylvania

  • CCOP - Geisinger Clinic and Medical Center - Danville
  • Allegheny General Hospital - Pittsburgh

Arizona

  • CCOP - Scottsdale Oncology Program - Scottsdale

Florida

  • Mayo Clinic - Jacksonville

Kansas

  • CCOP - Wichita - Wichita

Trial Details

FieldValue
Enrollment Target 157 participants
Start Date 2001-08
Est. Completion 2008-10
Phase Phase 2

Sponsor

Alliance for Clinical Trials in Oncology

446 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00022646

The ClinicalTrials.gov registry entry for NCT00022646 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 157 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (83% lower). The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which gemcitabine hydrochloride is the first listed.

NCT00022646 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Minnesota, Iowa, North Dakota.

Frequently Asked Questions

What is clinical trial NCT00022646 about?

NCT00022646 is a clinical study titled "Pemetrexed Disodium Plus Gemcitabine in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug and giving the drugs in different ways may kill more tumor cells. PURPOSE: Randomized phase II trial to compare the effectiveness of three different regi...

What is the current status of trial NCT00022646?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 157 participants. The study started on 2001-08. Estimated completion is 2008-10.

What conditions does trial NCT00022646 study?

This clinical trial studies the following conditions: Lung Cancer.

What interventions are being tested in trial NCT00022646?

The interventions under investigation include: gemcitabine hydrochloride (DRUG), pemetrexed disodium (DRUG).

Who is sponsoring clinical trial NCT00022646?

This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00022646 being conducted?

This trial has 20 study locations across Arizona, Florida, Illinois, Iowa, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lung Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.